Showing posts with label Parkinsons Disease. Show all posts
Showing posts with label Parkinsons Disease. Show all posts

Wednesday, 20 September 2017

Growth of Parkinsons Disease Market in Global Industry : Overview, Size and Share 2017

ResearchMoz presents professional and in-depth study of "Global Parkinsons Disease Market Report: 2016 Edition".

Parkinsons Disease (PD) is a chronic and progressive neurodegenerative or movement disorder which involves the malfunction and death of vital nerve cells in the brain, called neurons. Parkinsons primarily affects neurons in an area of the brain called the “substantia nigra”. The early signs and symptoms may be mild and may go unnoticed initially. The cause of this disease is mainly unknown with no cure till date but there exist several treatment options such as medications and surgery.

Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=715352

The current treatment market for Parkinsons disease has several unmet needs as no treatment has yet been successful in fully restoring the function that produces dopamine. However, the treatment currently only aims at controlling and relieving symptoms. The Parkinsons disease treatment market remains flooded by both branded and generic drugs. The market is expected to experience fluctuations in branded sales due to patent expiries and subsequent entry of generics in the market. Several biologics are under development for the treatment of Parkinsons along with possibility of developing “Stem Cell” as a treatment therapy.

The Parkinsons disease market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing healthcare expenditure and ageing population. The major growth drivers of the Parkinsons disease market includes rising level of toxin exposure, increasing life expectancy, rising male population worldwide, ageing population, healthcare expenditure and pesticide consumption. However, the growth of the market will also remain challenged by generic erosion, current treatment limitations and increasing risk of developing Melanoma.

The report, “Global Parkinsons disease Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific markets of the U.S., the European Union and Japan are being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth. 

Table of Content

1. Market Overview
1.1 Introduction   
1.2 Fundamental Features   
1.3 Types of Parkinson’s Disease   
1.4 Risk Factors   
1.5 Treatment Options

Make an Enquiry about TOC @ http://www.researchmoz.us/enquiry.php?type=E&repid=715352

2. Global Market
2.1 Global Parkinson’s Disease Drug Market by Value   
2.1.1 Global Parkinson’s Disease Drug Market by Region   
2.1.2 Global Parkinson’s Disease Market by Drug Class   
2.1.3 Global Parkinson’s Disease Patient Population by Severity   
2.1.4 Global Parkinson’s Disease Patient Population by Region

3. Regional Markets
3.1 The U.S.   
3.1.1 The U.S. Parkinson’s Disease Market by Value & Volume   
3.1.2 The U.S. Parkinson’s Disease Market Value by Category   
3.1.3 The U.S. Parkinson’s Disease Market Volume by Category   
3.1.4 The U.S. Parkinson’s Disease Market by Drug Class   
3.1.5 The U.S. Parkinson’s Disease Branded Drugs Market   
3.1.6 The U.S. Parkinson’s Disease Generic Drugs Market   
3.2 The European Union   
3.2.1 The E.U. Parkinson’s Patient Prevalence & Diagnosis
3.2.2 The European Parkinson’s Disease Drug Market by Value   
3.3 Japan   
3.3.1 Japan’s Parkinson’s Disease Drug Market by Value

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Level of Toxin Exposure   
4.1.2 Rising Life Expectancy   
4.1.3 Rising Male Population   
4.1.4 Increasing Ageing Population   
4.1.5 Global Healthcare Expenditure   
4.1.6 Pesticides Consumption
4.2 Trends

Browse Report @ http://www.researchmoz.us/global-parkinsons-disease-market-report-2016-edition-report.html

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Monday, 2 January 2017

Insights of Parkinsons Disease in Global Industry : Technology, Applications, Growth and Status 2016

Researchmoz added Most up-to-date research on "Parkinsons Disease - Pipeline Review, H2 2016" to its huge collection of research reports.

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease Pipeline Review, H2 2016, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

Parkinson's disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinsons disease. Parkinsons disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 30, 37, 5, 173, 42 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 1, 1, 50, 15 and 1 molecules, respectively.

Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=905719

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG